You are here: Home: Audio Program Guide: BCU Surgeons 3 | 2007 Audio: BCU Surgeons 3 | 2007
 
  Go to interview with Pat W Whitworth Jr, MD
Go to interview with Dennis J Slamon, MD, PhD
Go to interview with Paul E Goss, MD, PhD
Go to interview with Thomas B Julian, MD
Go to interview with Daniel F Hayes, MD
  To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Whitworth, MD Pat W Whitworth Jr, MD
Director, Nashville Breast Center
Clinical Associate Professor of Surgery
Vanderbilt University
Nashville, Tennessee
  
  Click here to download the entire interview  
Track 1 Injection techniques for sentinel lymph node biopsy (SLNB)
Track 2 SLNB in the neoadjuvant setting
Track 3 Studies of cryoablation in the treatment of breast cancer
Track 4 Potential advantages of cryoablation
Track 5 NSABP-B-39: Partial breast irradiation (PBI) versus whole breast irradiation
Track 6 Methods of PBI

Track 7 Impact of pathologists’ sampling on defining margin status
Track 8 Development of an assay for molecular analysis of sentinel lymph nodes
audio
Track 9 Treatment of patients with ductal carcinoma in situ (DCIS) and positive surgical margins
audio
Track 10 Utility of the Oncotype DX assay in predicting benefit from chemotherapy
audio
Track 11 TAILORx (Trial Assigning IndividuaLized Options for Treatment [Rx]): Prospective validation of the
Oncotype DX assay
audio
Track 12 ACOSOG-Z1031 trial evaluating aromatase inhibitors in the neoadjuvant setting
audio
Track 13 Neoadjuvant hormonal therapy for postmenopausal patients with hormone receptor-positive disease
Track 14 Aromatase inhibitors versus tamoxifen for postmenopausal patients with hormone receptor-positive
breast cancer
     
Slamon, MD Dennis J Slamon, MD, PhD
Professor of Medicine
Chief, Division of Hematology/Oncology
Director of Clinical/Translational Research
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California
  
  Click here to download the entire interview  
Track 1 Clinical trials of adjuvant trastuzumab
Track 2 Efficacy and cardiotoxicity of adjuvant trastuzumab in a nonanthracycline-based regimen
Track 3 Trastuzumab monotherapy
Track 4 Efficacy of trastuzumab in patients with small, node-negative, HER2-positive tumors
Track 5 Assessment of HER2 status by FISH versus IHC
     
Goss, MD Paul E Goss, MD, PhD
Professor of Medicine, Harvard Medical School
Director, Breast Cancer Program, MGH Cancer Center
Co-director of the Breast Cancer Disease Program, DF/HCC
Avon Foundation Senior Scholar
Boston, Massachusetts
  
  Click here to download the entire interview  
Track 1 Natural history of hormone receptor-positive versus hormone receptor-negative breast cancer
Track 2 Efficacy of delayed endocrine therapy
Track 3 Adjuvant therapy for premenopausal women with ER-positive, node-positive breast cancer
Track 4 Benefits and risks of oophorectomy for younger, premenopausal patients with hormone receptor-
positive breast cancer
Track 5 Unresolved issues in the use of adjuvant endocrine therapy for postmenopausal women
Track 6 Management of bone health in women being treated with aromatase inhibitors

Track 7 Arthralgias secondary to aromatase inhibitors
Track 8 Relationship between the insulin growth factor pathway and the pathogenesis of breast cancer
Track 9 Duration and delayed use of adjuvant trastuzumab
Track 10 TEACH trial: Extended adjuvant lapatinib versus placebo in trastuzumab-naïve, HER2-positive,
early breast cancer
     
Julian, MD Thomas B Julian, MD
Associate Professor, Human Oncology
Drexel University College of Medicine
Associate Director, Breast Care Center
Allegheny Cancer Center, Allegheny General Hospital
Pittsburgh, Pennsylvania
 
  Click here to download the entire interview  
Track 1 Use of MRI prior to breast-conserving surgery
Track 2 Clinical role of MRI in screening and diagnostic settings
Track 3 NSABP-B-40: Neoadjuvant chemotherapy in combination with bevacizumab
Track 4 NSABP-B-42: Letrozole in postmenopausal women who have completed five years of adjuvant
endocrine therapy
Track 5 Tolerability of aromatase inhibitors versus tamoxifen
Track 6 NSABP-B-39: Phase III study of adjuvant whole breast versus PBI for women with DCIS or Stage I or II
breast cancer
audio
Track 7 Role of the Oncotype DX assay in identifying a patient’s risk of recurrence
audio
Track 8 Testing algorithm to determine HER2 status
audio
Track 9 Clinical trials of trastuzumab in the neoadjuvant setting
audio
     
Hayes, MD Daniel F Hayes, MD
Professor of Internal Medicine
Clinical Director
Breast Oncology Program
Division of Hematology/Oncology
Department of Internal Medicine
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
  
  Click here to download the entire discussion  
Track 1 Predicting risk of recurrence and benefit from adjuvant chemotherapy
Track 2 Application of molecular biology and genetics to predict recurrence risk and response to chemotherapy
Track 3 Quality assurance of HER2 testing
Track 4 Clinical algorithm for assessment of HER2 status
Track 5 Use of the Oncotype DX assay for patients with hormone receptor-positive, node-negative, early breast cancer
audio
Track 6 Influence of tumor size in treatment decision-making
audio
Track 7 Rationale and description of TAILORx
audio
Track 8 Clinical approach to patients with hormone receptor-positive, HER2-positive, node-negative, early
breast cancer
audio
Track 9 Overview of the adjuvant trastuzumab clinical trial results
audio
Track 10 Revisiting nodal status to inform treatment decision-making
audio
Track 11 Risk of cardiotoxicity associated with adjuvant trastuzumab-containing regimens
audio
Track 12 Adjuvant hormonal therapy for postmenopausal patients
audio
Track 13 Tolerability, side effects and compliance with aromatase inhibitors
audio
Track 14 Clinical implications of the long natural history of hormone receptor-positive breast cancer
audio